Log in to search using one of your social media accounts:

 

Single-tablet Switch Option Effective in Virologically Suppressed HIV Single-tablet Switch Option Effective in Virologically Suppressed HIV
A new single-tablet regimen (STR) that includes the protease inhibitor (PI) darunavir, cobicistat, emtricitabine, and tenofovir alafenamide maintains viral suppression in adults infected with HIV-1, according to results from the EMERALD phase 3 noninferiority trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 20, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Janssen seeks approval for investigational regimen that aims to combine efficacy, durability, and the high genetic barrier to resistance of darunavir with the renal and bone safety profile of emtricitabine/tenofovir alafenamide in a once daily pill (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 19, 2017 Category: Pharmaceuticals Source Type: news

HIV prevention drug could save NHS £1 billion over 80 years
Conclusion Evidence to support the use of Prep is building. Studies have shown that it is very effective at reducing the chances of becoming infected with HIV, for men at risk of infection through unprotected sex with men. The question is more about the cost of treatment – and who should fund it – than whether it works. NHS England previously went to court to say that it should not be responsible for funding Prep, as it is a preventive treatment, and therefore should come under health promotion budgets held by local authorities. The High Court ruled that the NHS was able to fund the drug. NHS England has since ...
Source: NHS News Feed - October 19, 2017 Category: Consumer Health News Tags: Medication Source Type: news

Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens
EMERALD 48-week safety and efficacy results published in The Lancet HIV and to be presented at IDWeek (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 6, 2017 Category: Pharmaceuticals Source Type: news

Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1 Higher-Dose, Once-Daily Raltegravir Regimen for HIV-1
A 1,200-mg, once-daily regimen of raltegravir, in combination with tenofovir disoproxil fumarate and emtricitabine, is effective in patients with previously untreated HIV-1 infection, according to results from the ONCEMRK trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 26, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

New Guidelines Issued on HIV Treatment During Pregnancy (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Tenofovir-emtricitabine should not be a first treatment choice for women with HIV who are pregnant, according to new patient-centered … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 12, 2017 Category: Primary Care Source Type: news

Drug Helped Protect Gay Teen Males from HIV
Small study found Truvada worked when taken daily, but some strayed from regimen Source: HealthDay Related MedlinePlus Pages: Gay, Lesbian, Bisexual, and Transgender Health, HIV/AIDS, Teen Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 6, 2017 Category: Consumer Health News Source Type: news

Drug Helped Protect Gay Teen Males From HIV
Small study found Truvada worked when taken daily, but some strayed from regimen (Source: Fertility News - Doctors Lounge)
Source: Fertility News - Doctors Lounge - September 5, 2017 Category: Reproduction Medicine Tags: Infections, AIDS, Nursing, Pediatrics, Pharmacy, Reproductive Medicine, Research, News, Source Type: news

Drug Helped Protect Gay Teen Males From HIV
Small study found Truvada worked when taken daily, but some strayed from regimen (Source: WebMD Health)
Source: WebMD Health - September 5, 2017 Category: Consumer Health News Source Type: news

Truvada Helped Protect Gay Teen Males From HIV
TUESDAY, Sept. 5, 2017 -- A group of gay and bisexual teenage males safely used a medication that prevents HIV infection, though some failed to follow the drug regimen fully and became infected, researchers report. People at risk for becoming... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 5, 2017 Category: General Medicine Source Type: news

Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women Maraviroc-containing Regimens Appear Safe for HIV PrEP in Women
Maraviroc-containing regimens appear to be safe and well tolerated, compared with tenofovir-emtricitabine (TDF-FTC), for preventing HIV infection in women, according to results from a phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

PrEP use in US exceeds 100,000 in Gilead pharmacy survey
An estimated 120,000 people in the US have started Truvada for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences. (Source: PHPartners.org)
Source: PHPartners.org - August 16, 2017 Category: International Medicine & Public Health Source Type: news

Mylan rolls out HIV treatment medicine in Canada
Mylan launched three generic medications to treat HIV in Canada. The pharmaceutical company, which is based in the Netherlands but run out of its corporate offices in Canonsburg, said it had received Health Canada approval for these generic drugs: emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg, a generic alternative to Truvada efavirenz/emtricitabin e/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla tenofovir disoproxil 300 mg, a generic alternative… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 10, 2017 Category: American Health Authors: Paul J. Gough Source Type: news

Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan Pharmaceuticals ULC, a subsid... Biopharmaceuticals, Generics, Product Launch Mylan, Truvada, Atripla, Viread (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 10, 2017 Category: Pharmaceuticals Source Type: news

Gilead Announces U.S. FDA Priority Review Designation for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 10, 2017-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company ’s New Drug Application (NDA) for an... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 10, 2017 Category: Drugs & Pharmacology Source Type: news

Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz Lower Risk of Adverse Birth Outcomes With Tenofovir-emtricitabine-efavirenz
Exposure of infants, from conception, to the antiretroviral combination of tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TFC-FTC-EFV) is associated with a lower risk of adverse birth outcomes, compared with exposure to other antiretroviral regimens, according to data from Botswana.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

NY gay man was refused HIV drug 'because he has gay sex'
The man, who lives in New York, applied for Truvada's PrEP in July to protect himself from the life-threatening disease. But he received a denial letter from United, citing his sexuality as a reason. (Source: the Mail online | Health)
Source: the Mail online | Health - August 4, 2017 Category: Consumer Health News Source Type: news

Truvada, vaginal ring safe for HIV prevention in adolescents
New research has shown that the use of a monthly vaginal ring and a daily oral Truvada are safe and effective at preventing HIV in adolescent girls. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 25, 2017 Category: Consumer Health News Source Type: news

In adolescents, oral Truvada and vaginal ring for HIV prevention are safe, acceptable
NIH-funded clinical trials are first of their kind to include younger adolescent girls. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - July 25, 2017 Category: American Health Source Type: news

Janssen Receives Positive CHMP Opinion for SYMTUZA ™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
- Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tablet (Source: Johnson and Johnson)
Source: Johnson and Johnson - July 21, 2017 Category: Pharmaceuticals Source Type: news

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 12, 2017-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 12, 2017 Category: Drugs & Pharmacology Source Type: news

How approval of a low-price generic HIV prevention drug could hit Gilead
Foster City's Gilead Sciences won approval in 2012 of Truvada as the first drug to prevent the spread of the AIDS virus. What does it mean now that Teva Pharmaceutical Industries has won the OK to introduce a supposedly low-cost version of the drug? (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 10, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

How approval of a low-price generic HIV prevention drug could hit Gilead
Foster City's Gilead Sciences won approval in 2012 of Truvada as the first drug to prevent the spread of the AIDS virus. What does it mean now that Teva Pharmaceutical Industries has won the OK to introduce a supposedly low-cost version of the drug? (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 9, 2017 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves First Generic Truvada in US FDA Approves First Generic Truvada in US
Generic versions of emtricitabine/tenofovir disoproxil, which can both treat and prevent HIV infections, are already available in other countries.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news

Health Highlights: June 9, 2017
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Generic Version of HIV Drug Truvada Approved by FDA The first generic version of the HIV drug Truvada (emtricitabine and tenofovir disoproxil... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 9, 2017 Category: General Medicine Source Type: news

FDA Approves First Generic Truvada for HIV Infection and Pre-Exposure Prophylaxis (PrEP)
June 8, 2017 - The U.S. Food and Drug Administration has approved the first generic version of Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 8, 2017 Category: Pharmaceuticals Source Type: news

Gilead reports positive data from four Phase III combination trials for HIV-1
US-based biopharmaceutical firm Gilead Sciences has reported positive results from four Phase III clinical trials investigating the combination of bictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF) to treat patients with HIV-1. (Source: Drug Development Technology)
Source: Drug Development Technology - May 30, 2017 Category: Pharmaceuticals Source Type: news

A GOP Health Care Plan May Ruin Our Best Chance At Ending HIV And AIDS
Before the pharmacist retrieves my prescription, she leans in and whispers: “Just so you know, it’s $1,300.” This happens almost every time, so I already have at the ready my coupon card from the drug’s manufacturer. The card provides me with $3,600 in co-pays, or about three months worth of medicine, but now I’ve run out. I’m only on the hook for $80, after which I’ll hit my $7,150 health insurance deductible for the year. Then, until January, each monthly prescription will be free for me. I swipe my credit card. Between the manufacturer-provided discounts and my private health i...
Source: Healthy Living - The Huffington Post - May 16, 2017 Category: Consumer Health News Source Type: news

Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2017 Category: Drugs & Pharmacology Source Type: news

Atripla (Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 24, 2017 Category: Drugs & Pharmacology Source Type: news

Odefsey (Emtricitabine, Rilpivirine, and Tenofovir Alafenamide Fixed-dose Combination Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 20, 2017 Category: Drugs & Pharmacology Source Type: news

Scotland approves a controversial anti-HIV drug  
The Scottish Medicines Consortium (SMC) has approved the pre-exposure prophylaxis (PrEP) treatment, which has the brand name Truvada.A trial of the drug in England will start in 2017-18. (Source: the Mail online | Health)
Source: the Mail online | Health - April 11, 2017 Category: Consumer Health News Source Type: news

NHS' anti-HIV drug PrEP approved in Scotland, UK
The Scottish Medicines Consortium (SMC), UK, has approved the supply of Emtricitabine / tenofovir disoproxil (Truvada) by the National Health Service (NHS) to prevent HIV in the nation. (Source: Drug Development Technology)
Source: Drug Development Technology - April 10, 2017 Category: Pharmaceuticals Source Type: news

South Africa: Men Soon to Get HIV Prevention Pill
[Bhekisisa] By June, the health department will know more about how to roll out Truvada nationally to men who have sex with men. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - March 31, 2017 Category: Infectious Diseases Source Type: news

PrEP Is Making a Difference. Now Republicans Want to Make It Unaffordable
Evan J. Peterson learned about AIDS before he knew what “gay” meant. A child of the ‘80s, he recalls growing up in an age when he was constantly told that sex could kill him. “Having to form a sexual identity in that era was a burden,” he says. Now, Peterson takes Truvada, a pre-exposure prophylaxis (“PrEP”) that lowers his risk of contracting HIV by close to 99%. The once-a-day pill allows Peterson to say he’s negative with reasonable certainty, in addition to test results and the integrity of his sexual partners. “We have control of our own health,” he says. &ld...
Source: Healthy Living - The Huffington Post - March 8, 2017 Category: Consumer Health News Source Type: news

Stribild (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir DF) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 10, 2017 Category: Drugs & Pharmacology Source Type: news

Backed by strong numbers, Gilead takes to social media to market one-of-a-kind drug to prevent HIV
The success of the only FDA-approved drug to prevent infection of the AIDS virus — and the potential of reaching more people at risk of contracting HIV — is prompting Gilead Sciences Inc. to boost its direct-to-consumer marketing on Snapchat, Tumblr and other social media and dating sites. It is a somewhat controversial shift in Foster City-based Gilead's strategy around th e marketing of the drug, called Truvada, for what is known as pre-exposure prophylaxis, or PrEP. Before PrEP won Food and… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 8, 2017 Category: American Health Authors: Ron Leuty Source Type: news

Backed by strong numbers, Gilead takes to social media to market one-of-a-kind drug to prevent HIV
The success of the only FDA-approved drug to prevent infection of the AIDS virus — and the potential of reaching more people at risk of contracting HIV — is prompting Gilead Sciences Inc. to boost its direct-to-consumer marketing on Snapchat, Tumblr and other social media and dating sites. It is a somewhat controversial shift in Foster City-based Gilead's strategy around th e marketing of the drug, called Truvada, for what is known as pre-exposure prophylaxis, or PrEP. Before PrEP won Food and… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 8, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

Is PrEP Failing To Reach Those At The Highest Risk Of Contracting HIV?
The use of Truvada as PrEP—pre-exposure prophylaxis to prevent HIV—is going gangbusters. By the end of 2015, likely well over 80,000 U.S. residents had filled at least one prescription for the daily tablet. And given the steadily increasing rate of new prescriptions registered each quarter, the population of HIV-negative people who have at least tried PrEP has probably swelled considerably by now. This is fantastic news for the effort to stem the tide of HIV infections among men who have sex with men (MSM), whom data suggest make up the vast majority of PrEP users. While it’s still too early to determine ...
Source: Healthy Living - The Huffington Post - January 10, 2017 Category: Consumer Health News Source Type: news

CDC guidelines for HIV prevention regimen may not go far enough, study suggests
A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss some people who should be on it.Pre-exposure prophylaxis, or PrEP, is a measure that has proven to be highly effective in preventing HIV transmission during unprotected sex. While not entirely foolproof, studies have shown taking daily doses of tenofovir disoproxil-emtricitabine, or Truvada, is 92 percent effective in preventing HIV infection when taken correctly and consistently.Since 2012, the U.S. Centers fo...
Source: UCLA Newsroom: Health Sciences - January 7, 2017 Category: Universities & Medical Training Source Type: news

NIAID initiates Phase III HPTN 083 trial of anti-HIV drug
The National Institute of Allergy and Infectious Diseases (NIAID) in the US has initiated the Phase III HPTN 083 trial of cabotegravir and truvada to treat men and transgender women with HIV. (Source: Drug Development Technology)
Source: Drug Development Technology - December 22, 2016 Category: Pharmaceuticals Source Type: news

Genvoya (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 20, 2016 Category: Drugs & Pharmacology Source Type: news

HIV prevention trials network launches HPTN 083
(FHI360) The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). If found to be safe and effective for HIV pre-exposure prophylaxis, also known as PrEP, injectable CAB may be easier for some people to adhere to than daily oral TDF/FTC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2016 Category: Global & Universal Source Type: news

NIH launches first large trial of a long-acting injectable drug for HIV prevention
(NIH/National Institute of Allergy and Infectious Diseases) The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by NIH, will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every 8 weeks can safely protect men and transgender women from HIV infection at least as well as the anti-HIV medication Truvada taken daily as an oral tablet. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 20, 2016 Category: Infectious Diseases Source Type: news

NHS to launch three-year anti-HIV PrEP trial
Truvada drug to be made available to 10,000 people at risk (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 4, 2016 Category: Pharmaceuticals Source Type: news

Switching course, Gilead markets HIV drug for prevention
NEW YORK (Reuters) - Gilead Sciences Inc has begun marketing its HIV treatment Truvada in a way thousands of consumers already use it – to prevent infection with the virus that causes AIDS. (Source: Reuters: Health)
Source: Reuters: Health - November 30, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Tests to begin for HIV therapy injections, long-acting implants
Drugs from companies such as GlaxoSmithKline (NYSE:GSK), Gilead Sciences (NSDQ:GILD) and Merck (NYSE:MRK) are reportedly being considered for large-scale trials evaluating injectable HIV prevention therapies. Eventually, researchers hope to produce matchstick-sized implants that could provide year-long protection to vulnerable populations. Foster City, Calif.-based Gilead has a once-daily pill, Truvada, which prevents HIV infection during sex. Pre-exposure prophylaxis, also known as PrEP, can lessen the risk of catching the virus by more than 90% if the pill is taken regularly. Many patients, howev...
Source: Mass Device - November 29, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Implants Pharmaceuticals Research & Development Gilead Sciences GlaxoSmithKline plc Merck Source Type: news

Nurx raises $5.3M for app-based birth control and PrEP service
San Francisco-based Nurx, a telehealth company that offers prescriptions for birth control and HIV-prevention medication Truvada through an app, has raised $5.3 million in Series A funding in a round led by Union Square Ventures. Lowercase Capital, SV Angel and six Y Combinator partners also contributed. (Source: mobihealthnews)
Source: mobihealthnews - November 1, 2016 Category: Information Technology Source Type: news

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil)
This new medicine evidence summary reviewed 4 randomised trials of Truvada (emtricitabine/tenofovir disoproxil 200 mg/245 mg) for pre-exposure prophylaxis (PrEP) of HIV in either HIV-negative men or transgender women who have sex with men, or HIV-negative individuals in a heterosexual partnership with a person already infected with HIV. In these trials, Truvada reduced the relative risk of acquiring HIV infection by between 44% and 86% compared with placebo or no prophylaxis, which is equivalent to approximate numbers needed to treat of between 13 and 68 per year. In all trials, Truvada was given in addition to a comprehen...
Source: Current Awareness Service for Health (CASH) - October 6, 2016 Category: Consumer Health News Source Type: news

European Commission Clears Truvada for HIV PrEP European Commission Clears Truvada for HIV PrEP
Truvada is indicated for PrEP in combination with safer sex practices to reduce the risk for sexually acquired HIV-1 infection in adults at high risk.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 23, 2016 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news